A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01821040
Recruitment Status : Terminated
First Posted : March 29, 2013
Last Update Posted : April 10, 2015
Information provided by (Responsible Party):
Mundipharma Research Limited

Brief Summary:
The study compares the efficacy and safety of modified release prednisone versus immediate release prednisone in patients suffering from polymyalgia rheumatica.

Condition or disease Intervention/treatment Phase
Polymyalgia Rheumatica Drug: Lodotra® Drug: Prednisone IR (immediate release) Phase 3

Detailed Description:

The study consists of a screening phase, followed by a 4 week double-blind phase. During the double-blind phase, the patients will be randomised in a 1:1 ratio to either Lodotra® or immediate release prednisone (prednisone IR) plus respective placebo.

After completion of the double-blind phase, patients will be re-randomised in a 1:1 ratio to open-label Lodotra® or prednisone IR for 48 weeks. During the open-label phase, the dose of study medication will be tapered based on titration criteria.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 62 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomised, Multi-centre, Double-blind, Active-controlled, Parallel Group Study to Assess the Efficacy and Safety of Modified Release Prednisone (Lodotra®) Compared to Immediate Release Prednisone (Prednisone IR) in Subjects Suffering From Polymyalgia Rheumatica (PMR).
Study Start Date : March 2013
Actual Primary Completion Date : April 2014
Actual Study Completion Date : April 2014

Arm Intervention/treatment
Experimental: Lodotra®
Lodotra, starting dose of 15mg administered in the evening
Drug: Lodotra®
Lodotra, starting dose of 15mg administered in the evening
Other Name: Modified release prednisone

Active Comparator: Prednisone IR
Prednisone IR 15mg daily start dose (immediate release) administered in the morning
Drug: Prednisone IR (immediate release)
Prednisone IR 15mg daily start dose (immediate release) administered in the morning,

Primary Outcome Measures :
  1. To show that treatment with Lodotra® is noninferior to treatment with prednisone IR with regards to the percentage of complete responders. [ Time Frame: 4 weeks ]

Secondary Outcome Measures :
  1. Patient reported outcomes [ Time Frame: 4 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Males or females, 50 years of age or older who provided written informed consent.
  2. Females less than one year post-menopausal must have a negative serum or urine pregnancy test recorded prior to the first dose of study medication, be non-lactating, and willing to use adequate and highly effective methods of contraception throughout the study. A highly effective method of birth control is defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as sterilisation, implants, injectables, combined oral contraceptives, some IUDs (Intrauterine Device, hormonal), sexual abstinence or vasectomised partner).
  3. Subjects newly diagnosed with polymyalgia rheumatica and previously untreated with glucocorticoids for PMR. The diagnosis of polymyalgia rheumatica must be confirmed by all of the following criteria:

    • New onset bilateral shoulder pain or new onset bilateral shoulder and hip girdle pain.
    • PMR VAS score over the last 24 hours before the Screening Visit ≥ 50 (on a 0 - 100 scale).
    • Morning stiffness duration of ≥ 45 min on the day before the Screening Visit.
    • Acute phase response shown by elevated C-reactive protein (CRP; ≥ 2 times ULN).
  4. Subjects willing and able to participate in all aspects of the study and comply with the use of study medication.

Exclusion Criteria:

  1. Females who are pregnant (positive β-hCG test) or lactating.
  2. Subjects with any contraindication/history of hypersensitivity to predniso(lo)ne or other ingredients.
  3. Significant renal impairment (serume creatinine > 150 µmol/L).
  4. Significant hepatic impairment (ALT, AST and GGT > 2.5 ULN).
  5. Subjects suffering from another disease which requires glucocorticosteroid treatment. Topical glucocorticosteroids, e.g. intra-nasal or inhaled glucocorticosteroids are allowed but should be kept at a stable dose throughout the study.
  6. Continued use of systemic glucocorticoids within 4 weeks prior to the Screening Visit.
  7. Joint injections with glucocorticoids within 6 weeks prior to the Screening Visit.
  8. Subjects who require treatment with non-permitted concomitant therapies.
  9. Evidence of clinically significant cardiovascular, renal, hepatic, gastrointestinal or psychiatric disease at the time of screening, as determined by medical history, clinical laboratory tests, ECG results, and physical examination, that would place the subject at risk upon exposure to the study medication or that may confound the analysis and/or interpretation of the study results.
  10. Active alcohol or drug abuse.
  11. Subjects suffering from giant cell arteritis, late onset rheumatoid arthritis or other inflammatory rheumatoid diseases.
  12. Subjects suffering from drug-induced myalgia.
  13. Subjects suffering from fibromyalgia
  14. Subjects suffering from systemic lupus erythemathosus.
  15. Subjects suffering from neurological conditions, e.g. Parkinson's disease.
  16. Subjects suffering from active cancer.
  17. Subjects suffering from an active infection.
  18. Subjects who participated in a clinical research study involving a new chemical entity or an experimental drug within 30 days prior to the Screening Visit.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01821040

United Kingdom
Southend University Hospital
Westcliff on Sea, United Kingdom, SS9 9RY
Sponsors and Collaborators
Mundipharma Research Limited

Additional Information:
Responsible Party: Mundipharma Research Limited Identifier: NCT01821040     History of Changes
Other Study ID Numbers: LOD3501
2011-002353-57 ( EudraCT Number )
First Posted: March 29, 2013    Key Record Dates
Last Update Posted: April 10, 2015
Last Verified: April 2015

Keywords provided by Mundipharma Research Limited:
Polymyalgia rheumatica
Modified release prednisone

Additional relevant MeSH terms:
Polymyalgia Rheumatica
Giant Cell Arteritis
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Vasculitis, Central Nervous System
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Skin Diseases, Vascular
Skin Diseases
Autoimmune Diseases
Immune System Diseases
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents